Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement
31 janv. 2023 17h00 HE
|
Chembio Diagnostics, Inc.; Biosynex
Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide...
Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
28 nov. 2022 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the...
Chembio Diagnostics Reports Third Quarter 2022 Financial Results
03 nov. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases,...
Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
20 oct. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will...
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
06 sept. 2022 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it...
Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development
16 août 2022 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it...
Chembio Diagnostics Reports Second Quarter 2022 Financial Results
04 août 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases,...
Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will...
Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel
15 juin 2022 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., June 15, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the...
Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
24 mai 2022 16h15 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the...